Skip to main content
    C

    Cytokinetics Inc (CYTK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $53.17
    -2.96 (-5.27%)

    Market Cap: $7.82B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cytokinetics Inc (CYTK) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cytokinetics (CYTK) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Cytokinetics reported EPS of -$1.37, above the -$1.50 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/40)
    Avg Surprise
    -1.93%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.44
    Range-$1.58 - -$0.98
    24 analysts
    Revenue Consensus
    $66.72M
    Range$51.92M - $86.57M
    22 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.28
    Range-$1.55 - -$0.73
    6 analysts
    EPS Revisions
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.28-0.6%
    60d ago-$1.34+3.9%
    30d ago-$1.34+3.9%
    7d ago-$1.32+2.5%
    Current-$1.28
    Revenue Consensus
    $75.29M
    Range$56.44M - $95.40M
    6 analysts

    Next Report

    CYTK has an expected report date of Feb 22, 2027.

    CYTK Earnings Call

    The latest CYTK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CYTK beat 13, missed 24 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $47.56M, up 2351.5% from $1.94M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.37-$1.50-$1.65 - -$1.10+8.67%BeatN/A182 up, 0 downNov 4, 2026$47.56M
    Jun 30, 2026-$1.50-$1.63-$2.02 - -$1.26+7.98%BeatN/A159 up, 3 downAug 6, 2026$28.62M
    Mar 31, 2026-$1.67-$1.65-$1.79 - -$1.37-1.21%MissN/A130 up, 1 downMay 5, 2026$19.36M
    Dec 31, 2025-$1.50-$1.56-$1.77 - -$0.20+3.85%BeatN/A91 up, 2 downFeb 24, 2026$17.75M
    Sep 30, 2025-$1.54-$1.59-$2.55 - -$1.29+3.14%BeatN/A143 up, 0 downNov 5, 2025$1.94M
    Jun 30, 2025-$1.12-$1.34-$1.54 - -$0.35+16.42%BeatN/A170 up, 1 downAug 7, 2025$66.77M
    Mar 31, 2025-$1.36-$1.36-$1.59 - -$1.170.00%In lineN/A152 up, 2 downMay 6, 2025$1.58M
    Dec 31, 2024-$1.26-$1.17-$1.52 - -$0.30-7.33%MissN/A160 up, 0 downFeb 27, 2025$17.18M
    Sep 30, 2024-$1.36-$1.24-$1.46 - -$1.09-9.68%MissN/A161 up, 0 downNov 6, 2024$463000
    Jun 30, 2024-$1.31-$0.91-$1.38 - -$0.61-43.96%MissN/A160 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$1.33-$1.17-$1.35 - -$0.89-13.68%MissN/A152 up, 0 downMay 8, 2024$835000
    Dec 31, 2023-$1.38-$0.97-$1.47 - -$0.38-42.27%MissN/A170 up, 0 downFeb 27, 2024$1.67M
    Sep 30, 2023-$1.35-$0.76-$1.11 - -$0.40-77.63%MissN/A151 up, 0 downNov 2, 2023$378000
    Jun 30, 2023-$1.34-$1.24-$1.43 - -$0.31-8.06%MissN/A130 up, 0 downAug 3, 2023$867000
    Mar 31, 2023-$1.38-$1.18-$1.41 - -$1.03-16.95%MissN/A131 up, 0 downMay 4, 2023$4.61M
    Dec 31, 2022-$1.45-$1.21-$1.39 - -$0.97-19.83%MissN/A150 up, 0 downMar 1, 2023$1.96M
    Sep 30, 2022-$1.28-$1.17-$1.28 - -$1.06-9.40%MissN/A130 up, 0 downNov 3, 2022$2.52M
    Jun 30, 2022-$0.23-$1.01-$1.10 - -$0.95+77.23%BeatN/A100 up, 0 downAug 4, 2022$88.97M
    Mar 31, 2022-$1.02-$0.94-$1.04 - -$0.75-8.51%MissN/A110 up, 0 downMay 4, 2022$1.15M
    Dec 31, 2021-$0.36-$0.84-$1.00 - -$0.62+57.14%BeatN/A100 up, 0 downFeb 24, 2022$55.60M
    Sep 30, 2021-$0.95-$0.77-$0.93 - -$0.69-23.38%MissN/A8N/ANov 3, 2021$5.44M
    Jun 30, 2021-$0.86-$0.66-$0.70 - -$0.58-30.30%MissN/A9N/AAug 5, 2021$2.84M
    Mar 31, 2021-$0.66-$0.60-$0.68 - -$0.48-10.00%MissN/A8N/AMay 6, 2021$6.55M
    Dec 31, 2020-$0.62-$0.30-$0.60 - $0.63-106.67%MissN/A8N/AFeb 25, 2021$6.72M
    Sep 30, 2020-$0.05-$0.34-$0.64 - $1.26+85.29%BeatN/A8N/ANov 4, 2020$41.69M
    Jun 30, 2020-$0.68-$0.57-$0.61 - -$0.46-19.30%MissN/A7N/AAug 6, 2020$3.59M
    Mar 31, 2020-$0.66-$0.50-$0.55 - -$0.43-32.00%MissN/A6N/AMay 6, 2020$3.83M
    Dec 31, 2019-$0.52-$0.44-$0.54 - -$0.26-18.18%MissN/A6N/AMar 3, 2020$5.21M
    Sep 30, 2019-$0.50-$0.49-$0.57 - -$0.35-2.04%MissN/A5N/AOct 31, 2019$6.05M
    Jun 30, 2019-$0.56-$0.50-$0.56 - -$0.44-12.00%MissN/A5N/AAug 8, 2019$7.14M
    Mar 31, 2019-$0.54-$0.47-$0.50 - -$0.44-14.89%MissN/A5N/AMay 9, 2019$8.46M
    Dec 31, 2018-$0.48-$0.52-$0.58 - -$0.44+7.69%BeatN/A5N/AFeb 21, 2019$9.38M
    Sep 30, 2018-$0.40-$0.52-$0.56 - -$0.45+23.08%BeatN/A5N/ANov 1, 2018$10.64M
    Jun 30, 2018-$0.51-$0.51-$0.55 - -$0.460.00%In lineN/A5N/AJul 26, 2018$6.21M
    Mar 31, 2018-$0.56-$0.58-$0.61 - -$0.18+3.45%BeatN/A6N/AApr 26, 2018$5.27M
    Dec 31, 2017-$0.75-$0.70-$0.93 - -$0.38-7.14%Miss-568.8%7N/AFeb 15, 2018N/A
    Sep 30, 2017-$0.60-$0.62-$0.81 - -$0.39+3.23%Beat-181.1%7N/AOct 26, 2017$6.18M
    Jun 30, 2017-$0.60-$0.60-$0.74 - -$0.190.00%In lineN/A6N/AAug 2, 2017$3.05M
    Mar 31, 2017-$0.62-$0.61N/A-1.64%MissN/AN/AN/AApr 27, 2017$4.15M
    Dec 31, 2016$0.16-$0.26N/A+161.54%BeatN/AN/AN/AFeb 16, 2017$33.14M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.52, after -$5.26 the year before. It was $0.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.52N/A
    Dec 31, 2024-$5.26N/A
    Dec 31, 2023-$5.45N/A
    Dec 31, 2022-$3.98N/A
    Dec 31, 2021-$2.83N/A
    Dec 31, 2020-$2.01N/A
    Dec 31, 2019-$2.12N/A
    Dec 31, 2018-$1.95N/A
    Dec 31, 2017-$2.57-956.7%
    Dec 31, 2016$0.30N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,100 words across 25 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,08325
    2026Q2Jun 30, 20269,73126
    2026Q1Mar 31, 20263,8607
    2025Q4Dec 31, 20257,29816
    2025Q3Sep 30, 20257,70824
    2025Q2Jun 30, 20259,89621
    2025Q1Mar 31, 20259,92029
    2024Q4Dec 31, 20249,45725

    2026Q3 Earnings Call

    Opening remarks

    Diane Weiser Senior Vice President of Corporate Affairs Good afternoon, and thanks for joining us on the call today. The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com, along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of MYQORZO in the U.S. and Europe. Fady Malik, EVP of R&D, will provide updates related to aficamten. Steve Heitner, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter. Finally, Robert will make closing remarks. As you can see on this slide, today's discussion will include forward-looking statements, which are subject to risks and uncertainties. Please refer to our SEC filings for a discussion of these factors. And now I will turn the call over to Robert.

    Robert I. Blum President and Chief Executive Officer Thank you, Diane. And thanks to all for joining us on the call today. The third quarter was another period of strong execution for Cytokinetics as we continue to build a leading muscle-focused specialty cardiology company. In Q3, we made progress on each of our priorities underlying that strategy. Nearly nine months in, the launch of MYQORZO continues to exceed our expectations. In the third quarter, MYQORZO generated $44.5 million in net revenue, up 76% from Q2. As Andrew will describe, the number of prescribers prescribing per physician and patients dispensed all increased. We believe these trends reflect the differentiated profile of MYQORZO, and we see significant room for continued growth. Outside the United States, our launch in Germany is off to a strong start, and we continue to secure approvals in additional geographies, including recently in Canada and the United Kingdom. We expect to launch in the U.K. this quarter and in additional countries in 2027. We're also looking forward to the PDUFA date for data relating to MAPLE-HCM, which is November 14. Beyond oHCM, we're working diligently to bring aficamten to more patients living with HCM. In August, we presented the full results from ACACIA-HCM in a hotline session at ESC with simultaneous publication in the New England Journal of Medicine. In fact, the presentation was included in the opening plenary session for ESC, a clear sign of enthusiasm from the cardiology community, which today has no approved therapy that addresses the underlying disease for nHCM. We also presented additional results at ESC from prespecified analyses from ACACIA-HCM that further underscore the potential of aficamten in nHCM.

    Frequently Asked Questions About CYTK

    When is Cytokinetics's next earnings date?

    Cytokinetics's next earnings report is expected for Feb 22, 2027.

    Did CYTK beat earnings estimates last quarter?

    Yes. Cytokinetics reported EPS of -$1.37 for the quarter ended Sep 30, 2026, above the -$1.50 estimate, a 8.67% surprise.

    What EPS do analysts expect from CYTK next quarter?

    The consensus EPS estimate for Cytokinetics for the quarter ending Dec 31, 2026 is -$1.44 from 24 analysts, with estimates from -$1.58 to -$0.98.

    How often does CYTK beat earnings estimates?

    Cytokinetics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.94%.